Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 5
CAR T and Evolving Treatment Paradigms for Early R/R MM
Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.
Video Player is loading.
Video content above is prompted by the following:
- How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
- Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?
